Eltrombopag ITP denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Non-Formulary Denial for Eltrombopag in ITP

A non-formulary denial means eltrombopag is not listed on the specific UHC drug formulary attached to your plan, or it is placed on a tier that requires prior authorization, step therapy, or a formulary exception before coverage is granted. Formulary placement varies by plan year, employer contract, and state. Even when eltrombopag is clinically appropriate, a non-formulary denial is a coverage-structure issue rather than a clinical one — it can often be resolved through the formulary exception process, which exists precisely for situations where the formulary alternative is not medically suitable for a specific patient.

## Why This Denial Is Appealable

Federal regulations require plans to have a formulary exception process. If every formulary alternative is contraindicated, has already failed, or would cause clinically significant harm, the plan must consider covering the non-formulary drug. Under ACA §2719, you also have the right to internal appeal and external review for coverage denials. Under ERISA §503, employer-plan members are entitled to a full-and-fair review. The internal appeal window is typically 180 days from denial. External review must generally be initiated within 4 months of a final internal denial. An expedited process is available when urgency warrants it.

## Concrete Appeal Steps

1. Identify the formulary alternative(s): Request from UHC the name of the preferred TPO-RA or other ITP agent on the formulary. 2. Request a formulary exception: Submit a formulary exception request with supporting clinical documentation explaining why the listed alternative is not appropriate for this patient. 3. File an internal appeal if the exception is denied, escalating the clinical argument. 4. Request external review after exhausting internal options if the plan is subject to external review requirements.

## Documentation to Gather

• Formulary alternative history: records showing the patient has already tried and failed the preferred formulary option (dates, response, adverse effects), or a prescriber statement that the alternative is clinically contraindicated for this patient.
• Clinical-distinctiveness letter: a letter from the treating hematologist explaining what makes eltrombopag specifically necessary — oral administration, specific tolerability profile, or individual patient factors — compared to the formulary option.
• Diagnosis and severity documentation: platelet count history and ITP clinical notes establishing that treatment cannot be deferred while formulary issues are resolved.
• Prescriber medical-necessity letter: a direct statement that the formulary alternative is not an equivalent substitute for this patient.

## Criteria-Mapping Structure

Formulary exception decisions typically turn on two questions. Answer both with specific evidence:

| Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative is contraindicated or not clinically appropriate | Prescriber letter + chart documentation of why alternative cannot be used | | Patient has tried and failed the formulary alternative | Treatment history with dates, response recorded, and reason discontinued |

Review UHC's pharmacy formulary for your plan year (available in your member portal) and the UHC formulary exception request policy to ensure your submission addresses every required element. The FDA-approved prescribing label for eltrombopag can support the clinical rationale for why drug-specific properties matter to treatment selection.